A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid TumorsTaofeek K. Owonikoko, Fadlo R. Khuri, R. Donald Harvey et al.|Clinical Cancer Research|2020Cited by 14
Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.Omid Hamid, Marc S. Ernstoff, Stephen V. Liu et al.|Journal of Clinical Oncology|2021Cited by 12
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockadeEric J Miller, Matthew D. Galsky, Neeraj Agarwal et al.|Cancer|2024Cited by 2
Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibitionBrandon Wummer, Jacqueline T. Brown, Michael W. Schwartz et al.|Frontiers in Oncology|2025Cited by 1
Abstract CT303: A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumorsTaofeek K. Owonikoko, Fadlo R. Khuri, R. Donald Harvey et al.|Cancer Research|2015Cited by 0